Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Renvela“
Suchtreffer
Begriffe & Kennungen
Renvela · 4.8 Undesirable effects · 4
Eintrag öffnenRenvela · 4.8 · 6 MedDRA System Very common Common Very rare Not known Organ Class Immune system Hypersensitivity* disorders G
Eintrag öffnenRenvela · 4.8 · Adverse reactions that occurred during clinical trials or that were spontaneously reported from post- marketin
Eintrag öffnenRenvela · 4.8 · Adverse reactions that occurred during clinical trials or that were spontaneously reported from post- marketin
Eintrag öffnenRenvela · 4.8 · Adverse reactions that occurred during clinical trials or that were spontaneously reported from post- marketin
Eintrag öffnenRenvela · 4.8 · Adverse reactions that occurred during clinical trials or that were spontaneously reported from post- marketin
Eintrag öffnenRenvela · 4.8 · MedDRA System Very common Common Very rare Not known Organ Class Immune system Hypersensitivity* disorders Gas
Eintrag öffnenRenvela · 4.8 · MedDRA System Very common Common Very rare Not known Organ Class Immune system Hypersensitivity* disorders Gas
Eintrag öffnenRenvela · 4.8 · MedDRA System Very common Common Very rare Not known Organ Class Immune system Hypersensitivity* disorders Gas
Eintrag öffnenRenvela · 4.8 · Paediatric population In general, the safety profile for children and adolescents (6 to 18 years of age) is si
Eintrag öffnenRenvela · 4.8 · Paediatric population In general, the safety profile for children and adolescents (6 to 18 years of age) is si
Eintrag öffnenRenvela · 4.8 · Paediatric population In general, the safety profile for children and adolescents (6 to 18 years of age) is si
Eintrag öffnenRenvela · 4.8 · Paediatric population In general, the safety profile for children and adolescents (6 to 18 years of age) is si
Eintrag öffnenRenvela · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenRenvela · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenRenvela · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenRenvela · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenRenvela · 4.8 · Summary of the safety profile The most frequently occurring (≥ 5% of patients) adverse reactions were all in t
Eintrag öffnenRenvela · 4.8 · Summary of the safety profile The most frequently occurring (≥ 5% of patients) adverse reactions were all in t
Eintrag öffnenRenvela · 4.8 · Summary of the safety profile The most frequently occurring (≥ 5% of patients) adverse reactions were all in t
Eintrag öffnen